Menopur

DRUG4 trials

Sponsors

Ferring Pharmaceuticals A/S, Rigshospitalet, Denmark, Ferring Pharmaceuticals, New Hope Fertility Center

Conditions

AnovulationInfertilityInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle

Phase 3

A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme

Not yet recruitingCTIS2022-500308-23-00

Ferring Pharmaceuticals A/SInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle

Target: 115Updated: 2022-11-09

Phase 4

Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility

CompletedNCT01250821

Rigshospitalet, DenmarkAnovulation, Infertility

Start: 2010-12-31End: 2013-04-30Updated: 2013-04-19

Menopur Mixed Protocol

CompletedNCT01417195

Ferring PharmaceuticalsInfertility

Start: 2011-07-31End: 2012-01-31Updated: 2014-05-16

Unknown Phase

Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization

CompletedNCT02865681

New Hope Fertility CenterInfertility

Start: 2016-07-01End: 2017-06-07Updated: 2019-03-19